Kiniksa (KNSA) CAO sells 37,255 and 13,235 shares via 10b5-1

Kiniksa Pharmaceuticals (KNSA) insider transaction: The company’s Chief Accounting Officer exercised multiple vested stock options and sold shares on 10/20/2025 pursuant to a Rule 10b5-1 plan executed on May 24, 2025.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals (KNSA) insider transaction: The company’s Chief Accounting Officer exercised multiple vested stock options and sold shares on 10/20/2025 pursuant to a Rule 10b5-1 plan executed on May 24, 2025. Option exercises added 791 shares at $15.50, 6,195 at $12.97, 9,831 at $11.10, 9,831 at $11.97, and 12,787 at $10.76.

The insider then sold 37,255 shares at a weighted average price of $38.72 (trades ranged from $38.14 to $39.135) and 13,235 shares at a weighted average price of $39.31 (trades ranged from $39.145 to $39.57). After these transactions, the insider beneficially owned 27,046 Class A ordinary shares, held directly. The filing notes the options were fully vested and exercisable.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 12 txns

Insider Megna Michael R

Role CHIEF ACCOUNTING OFFICER

Sold 50,490 shs ($1.96M)

Approx. gross sale proceeds $1.96M

Approx. exercise cost $457K

Type	Security	Shares	Price	Value
Exercise	Share Option	791	$0.00	$0.00
Exercise	Share Option	6,195	$0.00	$0.00
Exercise	Share Option	9,831	$0.00	$0.00
Exercise	Share Option	9,831	$0.00	$0.00
Exercise	Share Option	12,787	$0.00	$0.00
Exercise	Class A Ordinary Share	791	$15.50	$12K
Exercise	Class A Ordinary Share	6,195	$12.97	$80K
Exercise	Class A Ordinary Share	9,831	$11.10	$109K
Exercise	Class A Ordinary Share	9,831	$11.97	$118K
Exercise	Class A Ordinary Share	12,787	$10.76	$138K
Sale	Class A Ordinary Share	37,255	$38.72	$1.44M
Sale	Class A Ordinary Share	13,235	$39.31	$520K

Holdings After Transaction: Share Option — 0 contracts (Direct); Class A Ordinary Share — 27,046 shares (Direct)

Footnotes (4)

1. F1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025.
2. F2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $38.14 and $39.135. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
3. F3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $39.145 and $39.57. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
4. F4. The option is fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kiniksa (KNSA) disclose in this Form 4?

The Chief Accounting Officer exercised vested stock options and sold shares on 10/20/2025 under a Rule 10b5-1 trading plan.

How many KNSA shares were sold and at what prices?

Sales were 37,255 shares at a weighted average $38.72 (range $38.14–$39.135) and 13,235 shares at a weighted average $39.31 (range $39.145–$39.57).

How many shares does the insider own after the transactions?

Beneficial ownership following the reported transactions is 27,046 Class A ordinary shares, held directly.

Which options were exercised by the KNSA insider?

Exercises covered 791 at $15.50, 6,195 at $12.97, 9,831 at $11.10, 9,831 at $11.97, and 12,787 at $10.76. The options were fully vested.

Was the trading under a 10b5-1 plan?

Yes. The transactions were effected pursuant to a 10b5-1 plan executed on May 24, 2025.

What is the insider’s role at Kiniksa?

The reporting person is an Officer, serving as Chief Accounting Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/22/2025 - 05:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Megna Michael R

(Last) (First) (Middle)

23 OLD BOND STREET, THIRD FLOOR

(Street)

LONDON X0 W1S 4PZ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF ACCOUNTING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
10/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	10/20/2025		M(1)		791	A	$15.5	38,892	D
Class A Ordinary Share	10/20/2025		M(1)		6,195	A	$12.97	45,087	D
Class A Ordinary Share	10/20/2025		M(1)		9,831	A	$11.1	54,918	D
Class A Ordinary Share	10/20/2025		M(1)		9,831	A	$11.97	64,749	D
Class A Ordinary Share	10/20/2025		M(1)		12,787	A	$10.76	77,536	D
Class A Ordinary Share	10/20/2025		S(1)		37,255	D	$38.72(2)	40,281	D
Class A Ordinary Share	10/20/2025		S(1)		13,235	D	$39.31(3)	27,046	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$15.5	10/20/2025		M(1)			791	(4)	09/09/2030	Class A Ordinary Share	791	$0	0	D
Share Option	$12.97	10/20/2025		M(1)			6,195	(4)	09/01/2031	Class A Ordinary Share	6,195	$0	0	D
Share Option	$11.1	10/20/2025		M(1)			9,831	(4)	04/06/2032	Class A Ordinary Share	9,831	$0	0	D
Share Option	$11.97	10/20/2025		M(1)			9,831	(4)	08/31/2032	Class A Ordinary Share	9,831	$0	0	D
Share Option	$10.76	10/20/2025		M(1)			12,787	(4)	03/31/2033	Class A Ordinary Share	12,787	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $38.14 and $39.135. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $39.145 and $39.57. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

4. The option is fully vested and exercisable.

	/s/ Douglas Barry, Attorney-in-Fact	10/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.